Literature DB >> 22828135

The resveratrol analog 4,4'-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells.

Cristina Maccario1, Monica Savio, Daniela Ferraro, Livia Bianchi, Roberto Pizzala, Luca Pretali, Luca Forti, Lucia Anna Stivala.   

Abstract

4,4'-dihydroxy-trans-stilbene (DHS) is a synthetic analog of resveratrol, a phytoalexin known for its biological activities. We previously demonstrated that DHS exerts an antiproliferative effect on normal human fibroblasts that is higher than that of the natural parent molecule. No evidence regarding its role in human cancer cell lines has been found thus far. In this study, we investigated the effects of DHS both on chemical-induced transformation of BALB/c 3T3 mouse fibroblasts and on the proliferation and invasion of human breast cancer MCF-7 cells. The results showed that DHS markedly suppresses the two-stage (3-methylcholanthrene plus 12-O-tetradecanoylphorbol-13-acetate) cell transformation. Compared with resveratrol, DHS inhibited both anchorage-dependent and -independent MCF-7 growth more efficiently. In addition, a reduction in the number of cells in S-phase, characterized by a concomitant increase in the levels of p21 and p53 proteins, together with a strong inhibition of pRb protein phosphorylation, was observed in DHS-treated cells. Furthermore, DHS effected a strong reduction in matrix metalloproteinase-2 and -9 activities, concomitantly with a marked inhibition of cell adhesion to the extracellular matrix components as well as inhibition of cell migration and invasion. Importantly, modulation of the adhesion molecule E-cadherin was also found in DHS-treated cells. Taken together, these results demonstrate that the two 4,4'-hydroxyl groups on the stilbenic backbone make DHS a more active molecule than resveratrol in inhibiting neoplastic transformation, cancer cell proliferation and invasion. In conclusion, this study suggests that DHS could be a promising anticancer agent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828135     DOI: 10.1093/carcin/bgs244

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

Review 1.  Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.

Authors:  James A McCubrey; Kvin Lertpiriyapong; Linda S Steelman; Steve L Abrams; Li V Yang; Ramiro M Murata; Pedro L Rosalen; Aurora Scalisi; Luca M Neri; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Paolo Lombardi; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello
Journal:  Aging (Albany NY)       Date:  2017-06-12       Impact factor: 5.682

Review 2.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

Review 3.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

4.  Solid Dispersions Incorporated into PVP Films for the Controlled Release of Trans-Resveratrol: Development, Physicochemical and In Vitro Characterizations and In Vivo Cutaneous Anti-Inflammatory Evaluation.

Authors:  Bruno Vincenzo Fiod Riccio; André Luiz Carneiro Soares do Nascimento; Andréia Bagliotti Meneguin; Camila Fernanda Rodero; Kaio Pini Santos; Rafael Miguel Sábio; Sarah Raquel de Annunzio; Carla Raquel Fontana; Hernane da Silva Barud; Priscileila Colerato Ferrari; Marlus Chorilli
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

5.  Normal fibroblasts induce E-cadherin loss and increase lymph node metastasis in gastric cancer.

Authors:  Wen Xu; Xinlei Hu; Zhongting Chen; Xiaoping Zheng; Chenjing Zhang; Gang Wang; Yu Chen; Xinglu Zhou; Xiaoxiao Tang; Laisheng Luo; Xiang Xu; Wensheng Pan
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

6.  2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2.

Authors:  Vitaliy M Sviripa; Wen Zhang; Andrii G Balia; Oleg V Tsodikov; Justin R Nickell; Florence Gizard; Tianxin Yu; Eun Y Lee; Linda P Dwoskin; Chunming Liu; David S Watt
Journal:  J Med Chem       Date:  2014-07-09       Impact factor: 7.446

7.  trans-4,4'-Dihydroxystilbene (DHS) inhibits human neuroblastoma tumor growth and induces mitochondrial and lysosomal damages in neuroblastoma cell lines.

Authors:  Bhaskar Saha; Birija Sankar Patro; Mrunesh Koli; Ganesh Pai; Jharna Ray; Sandip K Bandyopadhyay; Subrata Chattopadhyay
Journal:  Oncotarget       Date:  2017-05-16

8.  High Potency of a Novel Resveratrol Derivative, 3,3',4,4'-Tetrahydroxy-trans-stilbene, against Ovarian Cancer Is Associated with an Oxidative Stress-Mediated Imbalance between DNA Damage Accumulation and Repair.

Authors:  Justyna Mikuła-Pietrasik; Patrycja Sosińska; Marek Murias; Marcin Wierzchowski; Marta Brewińska-Olchowik; Katarzyna Piwocka; Dariusz Szpurek; Krzysztof Książek
Journal:  Oxid Med Cell Longev       Date:  2015-07-01       Impact factor: 6.543

9.  Resveratrol analogue 4,4'-dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis.

Authors:  Monica Savio; Daniela Ferraro; Cristina Maccario; Rita Vaccarone; Lasse D Jensen; Federica Corana; Barbara Mannucci; Livia Bianchi; Yihai Cao; Lucia Anna Stivala
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

Review 10.  Therapeutic Versatility of Resveratrol Derivatives.

Authors:  Waqas Nawaz; Zhongqin Zhou; Sa Deng; Xiaodong Ma; Xiaochi Ma; Chuangang Li; Xiaohong Shu
Journal:  Nutrients       Date:  2017-10-29       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.